Andere Sprachen Invex Therapeutics Ltd

Aktien

A2QMK9

AU0000048621

IXC

Markt geschlossen - Australian S.E. Andere Börsenplätze 04:26:51 08.05.2024			% 5 Tage	% 1. Jan.
0,078 ^AUD	-7,14 %		-2,50 %	-3,70 %

16.02.	Invex Therapeutics verringert Fiskal-H1-Verlust durch geringere F&E-Ausgaben	MT
15.02.	Invex Therapeutics Ltd berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Halbjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return	20.03.
Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses	16.02.
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	15.02.
Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	22.12.
Invex Therapeutics to Secure European Patent Grant for Neurological Medication	22.11.
Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director	08.11.
Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	17.08.23
Invex Therapeutics Ltd Announces Board Changes	03.07.23
Invex Therapeutics Jumps 19% After Securing Second European Orphan Drug Designation for Exenatide	23.06.23
Invex Therapeutics Secures Approval for IIH EVOLVE Phase III Trial in France; Shares Rise 7%	21.04.23
Israel's Ministry of Health Approves Invex Therapeutics' IIH EVOLVE Clinical Trial	20.04.23
Invex Therapeutics Secures Clearance for Phase 2 Neurological Trial in Germany; Shares Rise 4%	20.03.23
Invex Therapeutics Ltd Announces the Approval to Commence the IIH EVOLVE Phase III Clinical Trial	19.03.23
Invex Therapeutics Ltd. Announces the Publication of the Invex Phase II 'Pressure' Clinical Trial	13.03.23
Invex Therapeutics More Than Doubles Fiscal H1 Loss	17.02.23
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	16.02.23
Invex Therapeutics Opens First US Clinical Trial Site in Texas	19.01.23
Invex Therapeutics Ltd Announces First US Clinical Site Activated in IIH Evolve Phase III Clinical Trial	18.01.23
Invex Therapeutics Gains European Regulator Approval for Pediatric Plan	14.12.22
Invex Therapeutics Ltd Receives Approval for Paediatric Plan from the EMA	13.12.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Invex Therapeutics Ltd

Aktien

A2QMK9

AU0000048621

IXC

Andere Sprachen

Filter